COVID
RESOURCE CENTER

Altimmune is proud to be working on solutions to address the global SARS-CoV-2 pandemic. Using our proprietary intranasal vaccine technology, we have developed a novel COVID-19 vaccine candidate (AdCOVID™) with unique attributes designed to prevent infection and transmission of the virus.

We are also advancing development of a novel therapeutic candidate (T-COVID™) designed to protect patients with early COVID-19 infection from developing more severe symptoms and the need for hospitalization.

Read on to learn more about how AdCOVID™ and T-COVID™ can help in the fight against the SARS-CoV-2 coronavirus.

COVID-19 Product Pipeline

COVID-19 | AdCOVID and T-COVID™

AdCOVID

Single Dose Intranasal Vaccine

Key Attributes
  • Single dose vaccine that stimulates a broad immune response – neutralizing IgG, mucosal IgA and T cells
  • Promotes local mucosal immunity in the nasal cavity – critical for blocking both infection and transmission of the virus
  • Simple nasal delivery – does not require needles and is very well-tolerated
  • Scalable manufacturing – able to meet national and international demand
  • Room temperature stable for several months – allows for ease of distribution without refrigeration

T-COVID

Single Dose Intranasal Therapeutic

Key Attributes
  • Single dose intranasal therapeutic – designed to prevent severe disease and hospitalization
  • Designed for use in outpatient setting – reduces the burden on healthcare systems and healthcare providers
  • Works by modulating the innate immune response – decreases inflammatory cytokine release in the lungs
  • Acts rapidly – can provide protection within days of administration in preclinical studies

Our Intranasal Replication-Deficient Adenovirus 5 Vector Platform Technology

Timeline

Second Quarter 2021

Data readouts from AdCOVID and T-COVID clinical studies

February 2021

Commenced Phase 1 AdCOVID clinical trial

October 2020

Altimmune and UAB announce publication of compelling pre-clinical data for AdCOVID intranasal COVID-19 vaccine candidate

September 2020

Altimmune presents highlights of intranasal COVID-19 vaccine and therapeutic programs AdCOVID and T-COVID at the World Vaccine Congress

August 2020

Altimmune and the University of Alabama at Birmingham announce potent respiratory mucosal T cell responses in preclinical study of single-dose intranasal COVID-19 vaccine candidate, AdCOVID™

June 2020

Altimmune launches clinical trial of
T-COVID, an investigational intranasal immune modulator for the treatment of patients with early COVID-19

June 2020

Altimmune receives award from U.S. Department of Defense to fund Phase 1/2 clinical trial of T-COVID in outpatients with Early COVID-19

March 2020

Altimmune and the University of Alabama at Birmingham announce a collaboration on the development of single-dose, intranasal COVID-19 vaccine.

February 2020

Altimmune announced the advancement of a novel single-dose, intranasal vaccine and began advancing it toward animal testing and manufacturing.

FAQs

Why did Altimmune diversify into COVID-19 indications?

  • Altimmune believes its proprietary intranasal replication-deficient adenovirus 5 vector platform technology is ideally suited for rapid response to pandemic situations
  • Clinical research on the Company’s NasoVAX intranasal vaccine candidate for influenza, which is based on the same intranasal vaccine platform technology as AdCOVID, yielded impressive clinical results and Altimmune believes its platform technology has the potential to be effective in targeting COVID-19

What potential benefits does AdCOVID deliver?

  • Unlike traditional vaccines, which are delivered by intramuscular injection, AdCOVID is designed to be administered as a single-dose nasal spray, which has a number of potential benefits:
    • It is less invasive than an injection and it removes the need for trained healthcare personnel for vaccine administration
    • Unlike intramuscular vaccines, AdCOVID can stimulate a special type of local immunity known as mucosal immunity in the nasal cavity
    • We know that the nasal cavity is a key point of entry, replication and transmission for the virus that causes COVID-19 infection. Therefore, stimulating mucosal immunity directly in the nose could provide a more robust immune response to block viral infection in the recipient and prevent viral spread to others

When can AdCOVID be made available?

  • We were encouraged by the positive preclinical data that demonstrated AdCOVID’s ability to stimulate strong serum neutralizing activity, killer T cell responses in the lungs and potent mucosal immunity in the respiratory tract
  • Based on this strong data, we plan to start a Phase 1 clinical trial in the fourth quarter of this year
  • In parallel with these plans we are scaling up manufacturing of AdCOVID for advanced clinical trials and commercial production with the goal of ensuring AdCOVID is commercial-ready in 2021

What is the difference between AdCOVID and T-COVID?

  • AdCOVID is Altimmune’s intranasal vaccine candidate for COVID-19 and T-COVID is the Company’s intranasal therapeutic for outpatients with early COVID-19
  • AdCOVID and T-COVID work through different mechanisms to provide protection from COVID-19
  • AdCOVID works to prevent infection with the SARS-CoV-2 virus, and T-COVID works after infection, to protect patients from developing more severe symptoms and the need for hospitalization